Phase 2 × Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
TAILOR
Phase 2 Recruiting
320 enrolled
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Phase 2 Recruiting
33 enrolled
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Phase 2 Recruiting
80 enrolled
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting
249 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
168 enrolled
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Phase 2 Recruiting
52 enrolled
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Phase 2 Recruiting
30 enrolled
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
Phase 2 Recruiting
60 enrolled
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2 Recruiting
108 enrolled
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
120 enrolled
ReVenG
Phase 2 Recruiting
75 enrolled
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 Recruiting
40 enrolled
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 Recruiting
60 enrolled
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Phase 2 Recruiting
13 enrolled
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Phase 2 Recruiting
80 enrolled
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Phase 2 Recruiting
70 enrolled
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Phase 2 Recruiting
60 enrolled
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting
110 enrolled
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2 Recruiting
66 enrolled
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Recruiting
61 enrolled
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
Phase 2 Recruiting
86 enrolled
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Phase 2 Recruiting
155 enrolled
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 Recruiting
79 enrolled
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2 Recruiting
90 enrolled
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Phase 2 Recruiting
20 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Phase 2 Recruiting
40 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
27 enrolled
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Phase 2 Recruiting
20 enrolled
BOSon
Phase 2 Recruiting
40 enrolled
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Phase 2 Recruiting
230 enrolled
PIPOZA
Phase 2 Recruiting
40 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Recruiting
106 enrolled
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Phase 2 Recruiting
45 enrolled
VALUABLE
Phase 2 Recruiting
55 enrolled
FIGHT
Phase 2 Recruiting
53 enrolled